The Claim
Intermittent high-dose dexamethasone administration during paclitaxel-based chemotherapy in women with breast cancer is associated with a non-significant downward trend in morning serum cortisol and ACTH concentrations over 11 treatment cycles, suggesting potential but unconfirmed suppression of the HPA axis in this population.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In women with breast cancer receiving paclitaxel chemotherapy, intermittent high-dose dexamethasone is associated with a non-significant decrease in morning cortisol and ACTH levels across 11 treatment cycles.
See the scientific wording
Intermittent high-dose dexamethasone administration during paclitaxel-based chemotherapy in women with breast cancer is associated with a non-significant downward trend in morning serum cortisol and ACTH concentrations over 11 treatment cycles, suggesting potential but unconfirmed suppression of the HPA axis in this population.
A strong steroid medicine enters the brain and tells the hypothalamus and pituitary gland to stop making signals that tell the adrenal glands to produce stress hormones. As a result, the adrenal glands make less cortisol, and the brain makes less of the signal that triggers cortisol production.
What the research says
1 studyThe study found that in women getting a strong steroid medicine with their chemo, their morning stress hormone levels slightly went down over time — but not enough to say for sure it was because of the medicine. So it’s a hint, not proof, that the medicine might be affecting their body’s natural hormone system.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.